Personalized Medicine in Gynecological Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 9361
Special Issue Editors
2. Centro de Estudios Avanzados en Enfermedades Crónicas (ACCDiS), Independencia, Santiago 8380000, Chile
Interests: molecular biology; gastric cancer; ovarian cancer; molecular pathogenesis; bacterial infections; translational control; natural compounds
Interests: ovarian cancer; repurposing drugs; ovarian cancer treatments; new cancer markers; gynecological oncology; reproductive endocrinology
Interests: ovarian cancer; neurotrophins; angiogenesis; microRNAs for cancer treatment; ovarian cancer pathogenesis; neuroendocrine regulation of ovary
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gynecological cancer are a set of neoplasm that include ovarian cancer, cervical cancer and endometrial cancer as the most common pathologies. They represent a severe threat to women’s health, since their high incidence, high mortality, limited therapeutic late efficacy, recurrence, and the emergence of drug resistance. In general, the gynecological cancer diagnosis is mainly based on histopathological scoring with limited therapeutic options. In this context, the progress in personalized medicine, also known as “precision medicine” is vital to individualizing cancer care by treating tumors based on genetic and transcriptional patterns. To date, this notion has gone beyond nucleic acid signatures; thus, additional omic approaches (Big data) such as Proteomic, Metabolomic and Epigenetic have been developed to create novel targeted therapies for most cancer types. For instance, despite complete remission usually being reached in ovarian cancer, most tumors will recur within two years, and the rapid apparition of resistance to chemotherapy is observed. Thus, remission-maintenance regimens have included most personalized strategies and alternative therapies to overcome the problem of resistance and increase the survival of patients, including the use of anti-angiogenic molecules (Bevacizumab), PARP inhibitors, and directed immunotherapies. This point is even worse considering the genomic heterogeneity observed during the transition from the primary tumor to recurrence and metastasis.
The complexity and heterogeneity of gynecological cancer represent a tremendous opportunity for the development of personalized medicine; also, considering a most productive cross-talk between basic research and clinical application and the limitations imposed by particular regional situations in terms of technologic capacities and resources.
The journal Pharmaceuticals invites original articles and reviews to shed light on the challenges, opportunities, and current personalized therapies for the special issue “Personalized Medicine in Gynecological Cancer” of the journal. Topics include insight into the genetic characterization of gynecological cancers, new biomarkers for improving diagnosis and treatment, and new therapeutic approaches with a focus on targeted therapy.
Dr. Manuel Valenzuela-Valderrama
Dr. Maritza P. Garrido Palma
Prof. Dr. Carmen Aurora Romero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecological cancer
- personalized medicine
- ovarian cancer
- chemoresistance
- endometrial cancer
- cervical cancer
- OMICs
- personalized drug therapy
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
